MyMetabolon Login
© 2021 Metabolon, Inc. All rights reserved.
Metabolon Metabolon
  • Metabolomics
    • About Metabolomics
    • Our Process
    • Technology & Knowledgebase
    • Quality Assurance
    • Setting the Standard: The 4Cs
    • Our Latest Insights
  • Solutions
    • Column 1
      • Products & Services
        • Global Metabolomics
        • Lipidomics
        • Targeted Assays
        • Microbiome
        • Study Design & Consulting
        • Sample Preparation & Handling
        • Study Success Sample Handling Kit
        • Reporting & Interpretation
        • Bioinformatics
        • MyMetabolon Client Portal
    • Column 2
      • By Research & Development Phase
        • Discovery & Target Selection
        • Lead Candidate Selection
        • Preclinical
        • Clinical Development
        • Manufacturing & Bioprocessing
    • Column 3
      • By Therapeutic Area
        • Cardiovascular Disease
        • COVID-19
        • Diabetes
        • Gastrointestinal
        • Liver Disease
        • Neuroscience
        • Oncology
        • Renal & Urological Disorders
        • Respiratory Disorders
    • Column 4
      • By Sector
        • Academic
        • Agriculture
        • Biotech / Pharmaceutical
        • Precision Medicine
        • Nutrition
        • Personal Care & Cosmetics
        • Population Health
        • Veterinary & Animal Health
  • Insights
    • Our Latest Insights
    • Blog
    • News & Events
    • Publications
  • Resources
    • Resource Library
    • Client Stories
    • COVID-19
    • Publications
  • Company
    • About Us
    • Working With Us (FAQ)
    • Leadership
    • Careers
    • Strategic Partnering
    • News & Events
    • Contact Us
MyMetabolon
Demo Our Data
Metabolon
Demo Our Data
AnsweringCommonQuestionsMetabolomics

Webinar

Answering Common Questions about Metabolomics

Metabolomics can deliver new, actionable insights into systems biology, empowering biomarker discovery, and advancing research across the life sciences. However, as one of the lesser known ‘omics, many researchers do not yet fully understand how best to harness the full potential of these powerful data sets.

Join Metabolon, a global leader in global and targeted metabolomics, as we answer some of the most common questions asked about metabolomics and how researchers can incorporate metabolomic insights into their research. Kari Wong, Ph.D., Associate Director, Discovery & Translation Sciences, and Michael Fanelli, Business Development Executive – Strategic Accounts, Vinay Pawar, Ph.D., Application Scientist, and Paweł Gardzielewski, Ph.D., Business Development Executive, address your questions and offer valuable advice on how to ensure your study success.

Register & Watch
Back to Resource Library
  • 5 Risks Researchers take by not Prioritizing Metabolomics in Drug Development
    Previous Project5 Risks Researchers take by not Prioritizing Metabolomics in Drug Development
  • Next ProjectCloser to the Phenotype: Episode 2
    5 Risks Researchers take by not Prioritizing Metabolomics in Drug Development

Metabolomics

  • About Metabolomics
  • Our Process
  • Technology & Knowledgebase
  • Quality Assurance
  • Setting the Standard: The 4Cs
  • Insights & Discoveries

Solutions

  • Products & Services
  • By Research & Development Phase
  • By Therapeutic Area
  • By Sector

Insights

  • Our Latest Insights
  • Blog
  • News & Events
  • Publications

Resources

  • Resource Library
  • Client Stories
  • COVID-19

Company

  • About Us
  • Working With Us (FAQ)
  • Leadership
  • Careers
  • Strategic Partnering
  • News & Events
  • Contact Us
Metabolon - Logo - Enlightening Life

Metabolon provides actionable biological insights to answer the toughest questions in life sciences research and drug development.

© 2022 Metabolon, Inc. All rights reserved. Privacy & Terms

in
Copy